Abstract: A laser device comprises a first optical cavity comprising a first gain medium and a second optical cavity comprising a second gain medium. The first gain medium and the second gain medium generate light at respective different ranges of wavelengths. A synchronizer is optically coupled to both the first optical cavity and the second optical cavity and is configured to synchronize and mode-lock light from the first optical cavity and the second optical cavity. The laser device also includes a first optical filter and a second optical filter to filter the light from the first optical cavity and the second optical cavity respectively to output first filtered light pulses at a first predetermined range of wavelengths and second filtered light pulses at a second predetermined range of wavelengths.

Abstract: The present invention refers to an inhibitor of substance P and/or of its receptor for use in the treatment and/or prevention of stem cell deficiency. Preferably the inhibitor is an NK1 antagonist. Preferably the stem cell deficiency is a corneal epithelial stem cell deficiency. The invention also refers to pharmaceutical compositions containing the inhibitor for use in the treatment and/or prevention of stem cell deficiency.

Abstract: A sheet packaging material for producing a sealed package with a pourable food product; the packaging material has a quadrangular configuration with two boundary edges parallel to a longitudinal direction and two other boundary edges parallel to a transversal direction orthogonal to the longitudinal direction; the packaging material comprises two transversal crease lines extending transversally to the longitudinal direction and dividing the packaging material into: a bottom region containing a bottom crease pattern and configured to form a bottom portion of the package; a top region containing a top crease pattern and configured to form a top portion of the package; and an intermediate region contained between the transversal crease lines and designed to form a main portion of the package having a plurality of side wall portions; the intermediate region further comprises a plurality of V-shaped crease lines having respective vertices located on or adjacent to the transversal crease lines and at given points t

Abstract: A sealed package containing a pourable food product and comprising a bottom portion, a top portion and a main portion interposed between the bottom portion and top portion and including a plurality of side wall portions; the main portion is divided from the bottom portion and said top portion respectively by a bottom peripheral outline and a top peripheral outline extending transversally with respect to a longitudinal direction; each of the bottom peripheral outline and the top peripheral outline has a broken-line shape and is formed by a plurality of contour edges joined to each other; the bottom portion comprises a quadrilateral bottom panel delimited by the bottom peripheral outline and extending orthogonal to the longitudinal direction; the top portion comprises a quadrilateral top panel delimited by the top peripheral outline and extending transversally to the longitudinal direction; the area of the bottom panel is different from the area of a top quadrilateral obtained by projecting, along the longitudi

Abstract: The invention relates to compounds, in particular NK-1 antagonists, for use in the treatment of ocular sensitivity and/or ocular pain.

Abstract: There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.

Abstract: There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.

Abstract: There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.